Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Icosapent Ethyl (Vascepa): Canagliflozin has the stronger overall evidence (4.5 vs 4.2/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Canagliflozin wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Canagliflozin and Icosapent Ethyl (Vascepa) have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (canagliflozin)
Approved dose is 2 g twice daily (4 g/day total) taken with food, under a clinician, for statin-treated adults with elevated triglycerides and high cardiovascular risk. A prescription drug — not a self-directed regimen.
with-meals
Oral capsule — purified EPA ethyl ester (icosapent ethyl)
Unknown in humans
Months to years
Weeks to months
Throughout use
Months to years
Weeks
Weeks to months
Throughout use
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
The New England journal of medicine (2019) · Rct · n=8179
REDUCE-IT: 8,179 statin-treated patients with elevated triglycerides and high cardiovascular risk
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Journal of the American College of Cardiology (2019) · Rct · n=8179
REDUCE-IT secondary analysis of total (first plus recurrent) ischemic events
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the MARINE trial).
The American journal of cardiology (2011) · Rct
MARINE: randomized, placebo-controlled trial in patients with very high triglycerides (≥500 mg/dL)
Canagliflozin has a higher evidence score (4.5/10 vs 4.2/10) and wins in 1 of 3 categories.
For support heart health, Icosapent Ethyl (Vascepa) has a higher relevance score (72 vs 70).
No known interactions between Canagliflozin and Icosapent Ethyl (Vascepa) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.